G42 Healthcare Launches First UN38.3 Certified Proteomics Site in EMEA RegionProteomics is the study of proteins, their structures, and their functions in biological systems. It plays a crucial role in the development of diagnostic and therapeutic tools to improve patient outcomes. With the increasing demand for personalized medicine, proteomics has emerged as a powerful tool to identify biomarkers that can be used to diagnose diseases and predict treatment responses.However, proteomics is a complex and challenging field that requires state-of-the-art technologies, highly-skilled personnel, and strict quality control measures to ensure reproducibility and accuracy of results. This is where certification comes in.Certification is a voluntary process that involves a third-party assessment of an organization's quality management system to ensure compliance with relevant standards and regulations. It gives assurance to customers that the organization has the necessary expertise, resources, and commitment to deliver high-quality products and services.In the EMEA (Europe, Middle East and Africa) region, G42 Healthcare has taken the lead in proteomics certification by launching the first UN38.3 certified site in the industry. UN38.3 is a standard that regulates the transportation of lithium batteries and has been adapted to cover the transportation of hazardous goods, including biological specimens. The certification process involves a detailed assessment of the safety, handling, packaging, and transportation of biological samples to minimize the risk of contamination, damage, or loss.The certification of G42 Healthcares Somalogic Proteomics Laboratory is a major milestone for the company and the industry as a whole. It demonstrates their commitment to quality, safety, and innovation in the field of proteomics. It also gives confidence to customers that their samples are handled with the highest standards of care and that the results are reliable and accurate."We are proud to be the first UN38.3 certified Proteomics site in the EMEA region," said Ashraf Yehia, CEO of G42 Healthcare. "This certification validates our capabilities and expertise in the proteomics field and sets us apart from our competitors. It also demonstrates our commitment to providing our customers with the best possible service and results."With the growing demand for proteomics services, certification will become increasingly important for organizations to differentiate themselves and gain a competitive advantage. Customers will be more likely to choose certified providers who can assure them of quality, safety, and compliance.In conclusion, G42 Healthcare's certification is a significant development for the proteomics industry in the EMEA region. It sets a high standard for others to follow and shows that certification can be a powerful tool for quality assurance and customer satisfaction. As proteomics continues to advance and transform healthcare, certification will become an essential part of the industry landscape.
Read More
